Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for conditions characterized by high unmet medical needs, primarily focusing on central nervous system disorders, sleep-wake cycles, psychiatric illnesses, dermatologic conditions, and inflammatory responses. The company delves into the intricate mechanisms governing human physiology and behavior, particularly those that, when slightly askew, can profoundly impact daily life. From the precise timing of our internal biological rhythms that dictate sleep and wakefulness, to the complex neurochemical imbalances underlying severe mental health conditions, and even the body's sometimes overzealous reactions like motion-induced nausea or autoimmune attacks, Vanda aims to recalibrate these fundamental systems. It seeks to mend the subtle yet significant "bugs" in our biological code, offering pharmaceutical patches for conditions that disrupt the elegant, often overlooked, internal machinery that keeps us functioning.

Vanda's product portfolio includes HETLIOZ (tasimelteon), a melatonin receptor agonist for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances associated with Smith-Magenis Syndrome, though this former cash cow has recently faced the existential threat of generic erosion. Fanapt (iloperidone) is an atypical antipsychotic for schizophrenia and acute manic or mixed episodes of bipolar I disorder, while PONVORY (ponesimod) targets relapsing forms of multiple sclerosis. The company also offers NEREUS (tradipitant), a neurokinin-1 receptor antagonist for preventing motion-induced vomiting, which launched commercially in May 2026 via a direct-to-consumer web portal – because who doesn't want to skip the doctor for their seasickness? Its pipeline further explores treatments for generalized pustular psoriasis, hematologic malignancies, and social anxiety, among others.

Operating primarily in the United States, with a footprint extending to Canada and Europe, Vanda employs a specialty pharmaceutical business model. This involves high gross margins and significant investment in research and development, regulatory affairs, and intellectual property defense – a necessary shield in the cutthroat world of drug patents. The company leverages intellectual property, regulatory exclusivity, and clinical differentiation as key competitive advantages, often utilizing genetics and genomics in its drug discovery. Historically, Vanda has been no stranger to controversy, engaging in protracted legal battles with the FDA, notably over HETLIOZ for jet lag disorder and a partial clinical hold on tradipitant, where the company famously challenged the agency's insistence on 9-month dog studies, arguing they were both inhumane and scientifically questionable. Furthermore, past allegations of off-label promotion for Fanapt and Hetlioz, alongside claims of fraudulent reimbursement schemes, have added a dash of dark humor to its corporate narrative.